Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis

American Journal of Roentgenology

Volumn 172, Issue 5, 1999, Pages 1343-1346

  Tepe, Gunnar ^a   Schott, Ulrich ^a   Erley, Christiane M ^a   Albes, Johannes ^a   Claussen, Claus D ^a   Duda, Stephan H ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; UROKINASE;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EMBOLISM; FIBRINOLYTIC THERAPY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECURRENT DISEASE;

EID: 0032705316     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/ajr.172.5.10227513     Document Type: Article

References (13)

1. Ouriel K, Shortell CK, Azodo MVU, Guiterrez OH, Marder VJ. Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy. Radiology 1994;193:561-566
2. Ouriel K, Veith FJ, Sasahard AA (for the Thrombolysis Or Peripheral Arterial Surgery [TOPAS] Investigators). A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. New Engl J Med 1998;338:1105-1111
3. Friedman MF, Van der Bovenkamp EJ. The pathogenesis of coronary thrombus. Am J Pathol 1996;48:19-44
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696
6. Yasuda T, Gold HK, Leinbach RC, et al. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol 1990;16:1728-1735
7. Rutherford RB, Becker GJ. Standards of evaluating and reporting the results of surgical and percutaneous therapy for peripheral artery disease. J Vasc Interv Radiol 1991;2:169-174
8. Kandarpa K, Chopra PS, Aruny JE, et al. Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow infusion. Radiology 1993;188:861-867
9. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:33-42
10. Kleinman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381-389
11. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-854
12. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-935
13. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813